Vivin C 330mg+200mg Menarini 20 Effervescent Tablets

Product details

Therapeutic indications
Vivin C Tablets is used in case of headache and toothache, neuralgia, menstrual pain, rheumatic and muscular pain. Symptomatic therapy of feverish states and flu and cold syndromes.

Dosage and method of use
Vivin C Tablets should be taken in the following doses and methods:

Adults: 1-2 tablets if necessary up to 3-4 times a day.

Dissolve one or two Vivin C tablets in half a glass of still water. The product should be taken on a full stomach. Do not exceed the recommended doses: in particular elderly patients should follow the minimum doses indicated above.

Contraindications

Hypersensitivity to the active ingredients, to salicylates or to any of the excipients. Tendency to haemorrhages, gastropathies (eg gastro-duodenal ulcer), asthma. History of gastrointestinal bleeding or perforation related to previous active treatments or history of recurrent peptic ulcer / haemorrhage (two or more distinct episodes of proven ulceration or bleeding). Severe heart failure. The use of this medicine is contraindicated in children and young people under the age of 16. Dose> 100 mg / day during the third trimester of pregnancy

Special warnings
This medicinal product should not be used in children and young people under the age of 16. Cases of Reye's syndrome have been observed in children with viral infections (particularly chicken pox and flu-like conditions) and treated with acetylsalicylic acid. Reye's syndrome is manifested by persistent vomiting and signs of progressive damage to the central nervous system (numbness, leading to generalized convulsions and coma), signs of liver injury and hypoglycemia.

People older than 70 years of age, especially in the presence of concomitant therapies, should use this medicine only after consulting a doctor.
After three days of use at the maximum dose or after 5-7 days of continuous use, consult your doctor. It is advisable that patients with glucose-6-phosphate-dehydrogenase deficiency, chronic or recurrent gastric and intestinal disorders or impaired renal function be consulted with the doctor.

In the case of a sodium-free or low-sodium regimen, it should be noted that each tablet of the product contains about 480 mg of sodium. The use of VIVIN C should be avoided concomitantly with NSAIDs, including selective COX-2 inhibitors. Undesirable effects can be minimized with the use of the lowest effective dose for duration
of the shortest possible treatment needed to control symptoms.

Elderly: Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which can be fatal. Gastrointestinal bleeding, ulceration and perforation: Gastrointestinal bleeding, ulceration and perforation, which can be fatal, have been reported during treatment with all NSAIDs, at any time, with or without warning symptoms or a previous history of serious gastrointestinal events.

In the elderly and in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation, the risk of gastrointestinal bleeding, ulceration or perforation is higher with increased doses of NSAIDs. These patients should start treatment with the lowest available dose. Concomitant use of protective agents (misoprostol or proton pump inhibitors) should be considered for these patients and also for patients taking low doses of aspirin or other drugs that may increase the risk of gastrointestinal events.

Patients with a history of gastrointestinal toxicity, particularly the elderly, should report any unusual gastrointestinal symptoms (especially gastrointestinal bleeding) particularly in the initial stages of treatment. Caution should be exercised in patients taking concomitant medications they might
increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as aspirin.

When gastrointestinal bleeding or ulceration occurs in patients taking VIVIN C the treatment should be discontinued. NSAIDs should be administered with caution to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as these conditions can be exacerbated. Caution should be exercised in patients with a history of hypertension and / or heart failure as fluid retention and edema have been reported in association with NSAID therapy. Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis,
they have been reported very rarely in association with the use of NSAIDs. In the early stages of therapy, patients appear to be at the highest risk: onset
of the reaction occurs in most cases within the first month of treatment. VIVIN C should be discontinued at the first appearance of skin rash, mucosal lesions or any other signs of hypersensitivity.

Pregnancy and breastfeeding

Low doses (up to 100 mg / day)

Clinical studies indicate that doses up to 100 mg / day can be considered safe for use only in obstetrics, which requires specialist monitoring.

Doses of 100-500 mg / day

There are insufficient clinical data regarding the use of doses above 100 mg / day up to 500 mg / day. Therefore, the recommendations below for doses of 500 mg / day and above also apply to this dose range.

Doses of 500 mg / day and more

Inhibition of prostaglandin synthesis can adversely affect pregnancy and / or embryo / fetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk of cardiac malformations was increased from less than 1% to approximately 1.5%. It has been estimated that the risk increases with dose and duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to cause increased pre- and post-implantation loss and embryo-fetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular, has been reported in animals given prostaglandin synthesis inhibitors during the organogenetic period.

During the first and second trimester of pregnancy, acetylsalicylic acid should not be administered except in strictly necessary cases. If acetylsalicylic acid is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose and duration of treatment should be kept as low as possible.

During the third trimester of pregnancy, all prostaglandin synthesis inhibitors can expose the fetus to: cardiopulmonary toxicity (with premature closure of the arterial duct and pulmonary hypertension); renal dysfunction, which can progress to renal failure with oligo-hydroamnios. At the end of pregnancy, the mother and the newborn may be exposed to: possible prolongation of the bleeding time and antiplatelet effect which can occur even at very low doses; inhibition of uterine contractions resulting in delayed or prolonged labor.

Consequently, acetylsalicylic acid at doses> 100 mg / day is contraindicated during the third trimester of pregnancy.

Expiration and retention
Check the expiration date indicated on the package. The expiry date indicated on the package refers to the product in intact packaging, correctly stored. Store at a temperature not exceeding 25 ° C.

Warning: do not use the medicine after the expiry date indicated on the package.

Composition
Vivin C Tablets contains:
Active ingredient: acetylsalicylic acid 0.330 g, ascorbic acid 0.200 g
Excipients: glycine, anhydrous citric acid, sodium hydrogencarbonate, sodium benzoate